Disorders of water homeostasis

Renal and Electrolyte Disorders: Seventh Edition

Volumn , Issue , 2012, Pages 1-44

  Berl, Tomas ^a   Schrier, Robert W ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84974539516     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (138)

1. Smith H. From Fish to Philosopher: The Story of Our Internal Environment. Boston, MA: Little Brown; 1953.
2. Kuhn W, Ryffel K. Herstellung konzentrierter Losungen aus verdunnten durch blosse Membranwirkung: ein Modellversuch zur der Niere. Z Physiol Chem. 1942:145-180.
3. Knepper MA, Hoffert JD, Packer RK, et al. Urine concentration and dilution. In: Brenner BM, ed. The Kidney. 8th ed. Philadelphia, PA: WB Saunders;2008:308-329.
4. Kriz W. Structural organization of the renal medullary counterflow system. Fed Proc. 1983;42:2379-2385.
5. Nielsen S, Frokiaer J, Marples D, et al. Aquaporins in the kidney: from molecules to medicine. Physiol Rev. 2002;82:205-244.
6. Bagnasco SM, Peng T, Nakayama Y, et al. Differential expression of individual UT-A urea transporter isoforms in rat kidney. J Am Soc Nephrol. 2000;11:1980-1986.
7. Sands JM, Kokko JP. Countercurrent system. Kidney Int. 1990;38:695-699.
8. Chou SY, Porush JG, Faubert PF. Renal medullary circulation: hormonal control. Kidney Int. 1990;37: 1-13.
9. Verbalis J, Berl T. Disorders of water balance. In: Brenner BM, ed. The Kidney. 8th ed. Philadelphia: WB Saunders;2008:459-504.
10. Mohr E, Richter D. Sequence analysis of the promoter region of the rat vasopressin gene. FEBS Lett. 1990;260:305-308.
11. Brown DN, S. Cell Biology in vasopressin. In: Brenner BM, ed. The Kidney. 8th ed. Philadelphia, PA: WB Saunders; 2008:280-307.
12. Morel A, O'Carroll AM, Brownstein MJ, et al. Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature. 1992;356:523-526.
13. Lolait SJ, O'Carroll AM, McBride OW, et al. Cloning and characterization of a vasopressin V2receptor and possible link to nephrogenic diabetes insipidus. Nature. 1992;357:336-339.
14. Birnbaumer M, Seibold A, Gilbert S, et al. Molecular cloning of the receptor for human antidiuretic hormone. Nature. 1992;357:333-335.
15. Nielsen S, Chou CL, Marples D, et al. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci U S A. 1995;92:1013-1017.
16. Agre P, Sasaki S, Chrispeels MJ. Aquaporins: a family of water channel proteins. Am J Physiol. 1993;265:F461.
17. Nielsen SK, Knepper MK, Kwon T-H, et al. Regulation of water balance: urine concentration and dilution. In: Schrier RW, ed. Diseases of the Kidney and Urinary Tract. 8th ed: New York, NY: Lippincott Williams & Wilkins; 2007: 96-123.
18. Stricker EM, Verbalis JG. Water intake and body fluids. In: Zigmond MJ. Bloom FE, Landis SC. Roberts JL, Squire LR, eds. Fundamental Neuroscience. San Diego; 1999:111-126.
19. Fitzsimons JT. Angiotensin, thirst, and sodium appetite. Physiol Rev. 1998;78:583-686.
20. Perez GO, Oster JR, Robertson GL. Severe hypernatremia with impaired thirst. Am J Nephrol. 1989;9:421-434.
21. Berl T, Anderson RJ, McDonald KM, et al. Clinical disorders of water metabolism. Kidney Int. 1976;10: 117-132.
22. Maghnie M, Cosi G, Genovese E, et al. Central diabetes insipidus in children and young adults. N Engl J Med. 2000;343:998-1007.
23. Kaltsas GA, Powles TB, Evanson J, et al. Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. J Clin Endocrinol Metab. 2000;85:1370-1376.
24. Rittig S, Robertson GL, Siggaard C, et al. Identification of 13 new mutations in the vasopressin-neurophysin II gene in 17 kindreds with familial autosomal dominant neurohypophyseal diabetes insipidus. Am J Hum Genet. 1996;58: 107-117.
25. Russell TA, Ito M, Yu RN, et al. A murine model of autosomal dominant neurohypophyseal diabetes insipidus reveals progressive loss of vasopressin-producing neurons. J Clin Invest. 2003;112:1697-1706.
26. Hardy C, Khanim F, Torres R, et al. Clinical and molecular genetic analysis of 19 Wolfram syndrome kindreds demonstrating a wide spectrum of mutations in WFS1. Am J Hum Genet. 1999;65: 1279-1290.
27. Fraser CL, Arieff AI. Fatal central diabetes mellitus and insipidus resulting from untreated hyponatremia: a new syndrome. Ann Intern Med. 1990;112: 113-119.
28. Kurokawa H, Fujisawa E, Nakano Y, et al. Posterior lobe of the pituitary gland: correlation between signal intensityon T1-weighted MR images and vasopressin concentration. Radiology. 1998:79-83.
29. De Wardener HE, Herxheimer A. The effect of a high water intake on the kidney's ability to concentrate the urine in man. 1957. J Am Soc Nephrol. 2000;11:980-987.
30. Kanno K, Sasaki S, Hirata Y, et al. Urinary excretion of aquaporin-2 in patients with diabetes insipidus. N Engl J Med. 1995;332:1540-1545.
31. Saito T, Higashiyama M, Nakamura T, et al. Urinary excretion of the aquaporin-2 water channel exaggerated in pathological states of impaired water excretion. Clin Endocrinol (Oxf). 2001;55:217-221.
32. Seck JR DD. Diabetes insipidus: current treatment recommendation. Drugs. 1992:216-224.
33. Fjellestad-Paulsen A, Tubiana-Rufi N, Harris A, et al. Central diabetes insipidus in children. Antidiuretic effect and pharmacokinetics of intranasal and peroral 1-deamino-8-D-arginine vasopressin. Acta Endocrinol (Copenh). 1987;115: 307-312.
34. Dunn AL, Powers JR, Ribeiro MJ, et al. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia. 2000;6:11-14.
35. Robson WL, Norgaard JP, Leung AK. Hyponatremia in patients with nocturnal enuresis treated with DDAVP. Eur J Pediatr. 1996;155:959-962.
36. Bichet DG. Nephrogenic and central diabetes insipidus. In: Schrier RW, ed. Diseases of the Kidney and Urinary Tract. 8th ed. New York, NY: Lippincott Williams & Wilkins; 2007:2249-2269.
37. Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005;16:2836-2846.
38. Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol. 2006;17:1820-1832.
39. Deen PM, Croes H, van Aubel RA, et al. Water channels encoded by mutant aquaporin-2 genes in nephrogenic diabetes insipidus are impaired in their cellular routing. J Clin Invest. 1995;95: 2291-2296.
40. Tamarappoo BK, Verkman AS. Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones. J Clin Invest. 1998;101:2257-2267.
41. Kuwahara M, Iwai K, Ooeda T, et al. Three families with autosomal dominant nephrogenic diabetes insipidus caused by aquaporin-2 mutations in the C-terminus. Am J Hum Genet. 2001;69:738-748.
42. King LS, Choi M, Fernandez PC, et al. Defective urinary-concentrating ability due to a complete deficiency of aquaporin-1. N Engl J Med. 2001; 345:175-179.
43. Ma T, Song Y, Yang B, et al. Nephrogenic diabetes insipidus in mice lacking aquaporin-3 water channels. Proc Natl Acad Sci USA. 2000;97: 4386-4391.
44. Bouley R, Hasler U, Lu HA, et al. Bypassing vasopressin receptor signaling pathways in nephrogenic diabetes insipidus. Semin Nephrol. 2008;28:266-278.
45. Bernier V, Morello JP, Zarruk A, et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol. 2006;17:232-243.
46. Tannen RL, Regal EM, Dunn MJ, et al. Vasopressin-resistant hyposthenuria in advanced chronic renal disease. N Engl J Med. 1969;280: 1135-1141.
47. Teitelbaum I, McGuinness S. Vasopressin resistance in chronic renal failure. Evidence for the role of decreased V2 receptor mRNA. J Clin Invest. 1995;96:378-385.
48. Kwon TH, Frokiaer J, Knepper MA, et al. Reduced AQP1, -2, and -3 levels in kidneys of rats with CRF induced by surgical reduction in renal mass. Am J Physiol. 1998;275: F724-F741.
49. Marples D, Frokiaer J, Dorup J, et al. Hypokalemia-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. J Clin Invest. 1996;97:1960-1968.
50. Sands JM, Flores FX, Kato A, et al. Vasopressin-elicited water and urea permeabilities are altered in IMCD in hypercalcemic rats. Am J Physiol. 1998; 274:F978-F985.
51. Earm JH, Christensen BM, Frokiaer J, et al. Decreased aquaporin-2 expression and apical plasma membrane delivery in kidney collecting ducts of polyuric hypercalcemic rats. J Am Soc Nephrol. 1998;9:2181-2193.
52. Marples D, Christensen S, Christensen EI, et al. Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest. 1995;95:1838-1845.
53. Rao R, Zhang MZ, Zhao M, et al. Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria. Am J Physiol Renal Physiol. 2005;288: F642-F649.
54. Cadnapaphornchai MA, Summer SN, Falk S, et al. Effect of primary polydipsia on aquaporin and sodium transporter abundance. Am J Physiol Renal Physiol. 2003;285:F965-F971.
55. Sands JM, Naruse M, Jacobs JD, et al. Changes in aquaporin-2 protein contribute to the urine concentrating defect in rats fed a low-protein diet. J Clin Invest. 1996;97:2807-2814.
56. Durr JA, Hoggard JG, Hunt JM, et al. Diabetes insipidus in pregnancy associated with abnormally high circulating vasopressinase activity. N Engl J Med. 1987;316:1070-1074.
57. Adrogue HJ, Madias NE. Hypernatremia. N Engl J Med. 2000;342:1493-1499.
58. Lien YH, Shapiro JI, Chan L. Effects of hypernatremia on organic brain osmoles. J Clin Invest. 1990;85:1427-1435.
59. Palevsky PM, Bhagrath R, Greenberg A. Hypernatremia in hospitalized patients. Ann Intern Med. 1996;124:197-203.
60. Polderman KH, Schreuder WO, Strack van Schijndel RJ, et al. Hypernatremia in the intensive care unit: an indicator of quality of care? Crit Care Med. 1999;27:1105-1108.
61. Thurman J, Berl T. Therapy in nephrology and hypertension. In: Wilcox CS, ed. Therapy in Nephrology and Hypertension. 3 ed. Philadelphia, PA: WB Saunders; 2008:337-352
62. Blum D, Brasseur D, Kahn A, et al. Safe oral rehydration of hypertonic dehydration. J Pediatr Gastroenterol Nutr. 1986;5:232-235.
63. Kahn A, Brachet E, Blum D. Controlled fall in natremia and risk of seizures in hypertonic dehydration. Intensive Care Med. 1979;5:27-31.
64. Kumar S, Berl T. Sodium. Lancet. 1998;352:220-228.
65. Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med. 1999;106:399-403.
66. Nguyen MK, Ornekian V, Butch AW, Kurtz I. A new method for determining plasma water content: application in pseudohyponatremia. Am J Physiol Renal Physiol. 2007;292:F1652-1656.
67. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342:1581-1589.
68. Parikh C, Berl T. Disorders of water metabolism. In: London MI, ed. Comprehensive Clinical Nephrology. 4 ed. In press.
69. Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008;52: 144-153.
70. Ohara M, Cadnapaphornchai MA, Summer SN, et al. Effect of mineralocorticoid deficiency on ion and urea transporters and aquaporin water channels in the rat. Biochem Biophys Res Commun. 2002;299:285-290.
71. Palmer BF. Hyponatraemia in a neurosurgical patient: syndrome of inappropriate antidiuretic hormone secretion versus cerebral salt wasting. Nephrol Dial Transplant. 2000;15:262-268.
72. Sterns RH, Silver SM. Cerebral salt wasting versus SIADH: what difference? J Am Soc Nephrol. 2008;19:194-196.
73. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577-585.
74. Schrier RW, Gurevich AK, Cadnapaphornchai MA. Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis. Semin Nephrol. 2001;21:157-172.
75. Martin PY, Abraham WT, Lieming X, et al. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol. 1999;10:2165-2170.
76. Abraham WT, Shamshirsaz AA, McFann K, et al. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist in New York Heart Association functional class II and III chronic heart failure patients.J Am Coll Cardiol. 2006;47:1615-1621.
77. Sica DA. Hyponatremia and heart failure-pathophysiology and implications. Congest Heart Fail. 2005;11:274-277.
78. Xu DL, Martin PY, Ohara M, et al. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest. 1997;99:1500-1505.
79. Claria J, Jimenez W, Arroyo V, et al. Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. Gastroenterology. 1989;97:1294-1299.
80. Inoue T, Ohnishi A, Matsuo A, et al. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther. 1998;63:561-570.
81. Martin PY, Ohara M, Gines P, et al. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J Clin Invest. 1998;101:235-242.
82. Weigert AL, Martin PY, Niederberger M, et al. Endothelium-dependent vascular hyporesponsiveness without detection of nitric oxide synthase induction in aortas of cirrhotic rats. Hepatology. 1995;22:1856-1862.
83. Fernandez-Llama P, Jimenez W, Bosch-Marce M, et al. Dysregulation of renal aquaporins and Na-Cl cotransporter in CCl4-induced cirrhosis. Kidney Int. 2000;58:216-228.
84. Apostol E, Ecelbarger CA, Terris J, et al. Reduced renal medullary water channel expression in puromycin aminonucleoside-induced nephrotic syndrome. J Am Soc Nephrol. 1997;8:15-24.
85. Gross PR, Rascher W. Vasopressin and hyponatremia in renal insufficiency. Contrib Nephrol. 1986:54.
86. Celkjers W. Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism. N Engl J Med. 1989:492-496.
87. Wang W, Li C, Summer SN, et al. Molecular analysis of impaired urinary diluting capacity in glucocorticoid deficiency. Am J Physiol Renal Physiol. 2006;290:F1135-F1142.
88. Berghorn KA, Knapp LT, Hoffman GE, et al. Induction of glucocorticoid receptor expression in hypothalamic magnocellular vasopressin neurons during chronic hypoosmolality. Endocrinology. 1995;136:804-807.
89. Hanna FW, Scanlon MF. Hyponatraemia, hypothyroidism, and role of arginine-vasopressin. Lancet. 1997;350:755-756.
90. Iwasaki Y, Oiso Y, Yamauchi K, et al. Osmoregulation of plasma vasopressin in myxed-ema. J Clin Endocrinol Metab. 1990;70:534-539.
91. Chen YC, Cadnapaphornchai MA, Yang J, et al. Nonosmotic release of vasopressin and renal aquaporins in impaired urinary dilution in hypothyroidism. Am J Physiol Renal Physiol. 2005;289:F672-678.
92. Riggs AT, Dysken MW, Kim SW, et al. A review of disorders of water homeostasis in psychiatric patients. Psychosomatics. 1991;32:133-148.
93. de Leon J, Verghese C, Tracy JI, et al. Polydipsia and water intoxication in psychiatric patients: a review of the epidemiological literature. Biol Psychiatry. 1994;35:408-419.
94. Berl T. Psychosis and water balance. N Engl J Med. 1988;318:441-442.
95. Musch W, Xhaet O, Decaux G. Solute loss plays a major role in polydipsia-related hyponatraemia of both water drinkers and beer drinkers. QJM. 2003;96:421-426.
96. Anderson RJ, Chung HM, Kluge R, et al. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med. 1985;102:164-168.
97. Hoorn EJ, Geary D, Robb M, et al. Acute hyponatremia related to intravenous fluid administration in hospitalized children: an observational study. Pediatrics. 2004;113:1279-1284.
98. Arieff AI. Permanent neurological disability from hyponatremia in healthy women undergoing elective surgery. Ann Intern Med. 1986;102:164.
99. Palmer B, Sterns, RH. Fluid, electrolytes, and acid-base disturbances. NephSAP. 2009:70-167.
100. Aphnis E, Stylianou K, Alexandrakis M, et al. Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy. Nephron Clin Pract. 2007;106:c143-c148.
101. Bouman WP, Pinner G, Johnson H. Incidence of selective serotonin reuptake inhibitor (SSRI) induced hyponatraemia due to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion in the elderly. Int J Geriatr Psychiatry. 1998;13:12-15.
102. Holmes SB, Banerjee AK, Alexander WD. Hyponatraemia and seizures after ecstasy use. Postgrad Med. J 1999;75:32-33.
103. Almond CS, Shin AY, Fortescue EB, et al. Hyponatremia among runners in the Boston Marathon. N Engl J Med. 2005;352:1550-1556.
104. Hew-Butler T, Jordaan E, Stuempfle KJ, et al. Osmotic and nonosmotic regulation of arginine vasopressin during prolonged endurance exercise. J Clin Endocrinol Metab. 2008;93: 2072-2078.
105. Verbalis JG. Pathogenesis of hyponatremia in an experimental model of the syndrome of inappropriate antidiuresis. Am J Physiol. 1994;267:R1617-1625.
106. Ecelbarger CA, Chou CL, Lee AJ, et al. Escape from vasopressin-induced antidiuresis: role of vasopressin resistance of the collecting duct. Am J Physiol. 1998;274:F1161-1166.
107. Ecelbarger CA, Nielsen S, Olson BR, et al. Role of renal aquaporins in escape from vasopressin-induced antidiuresis in rat. J Clin Invest. 1997;99: 1852-1863.
108. Miller M. Hyponatremia: age-related risk factors and therapy decisions. Geriatrics. 1998;53:32-42.
109. Zerbe R, Stropes L, Robertson G. Vasopressin function in the syndrome of inappropriate antidiuresis. Annu Rev Med. 1980;31:315-327.
110. Decaux G, Vandergheynst F, Bouko Y, et al. Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree. J Am Soc Nephrol. 2007;18:606-612.
111. Verbalis J. SIADH and other hypoosmolar. In: Schrier RW, ed. Diseases of the Kidney and Urinary Tract. 8th ed. New York, NY: Lippincott Williams & Wilkins;2007:2214.
112. Papadopoulos MC, Verkman AS. Aquaporin-4 and brain edema. Pediatr Nephrol. 2007;22:778-784.
113. Yang B, Zador Z, Verkman AS. Glial cell aquaporin-4 overexpression in transgenic mice accelerates cytotoxic brain swelling. J Biol Chem. 2008;283:15280-15286.
114. Ayus JC, Varon J, Arieff AI. Hyponatremia, cerebral edema, and noncardiogenic pulmonary edema in marathon runners. Ann Intern Med. 2000;132:711-714.
115. Ayus JC, Wheeler JM, Arieff AI. Postoperative hyponatremic encephalopathy in menstruant women. Ann Intern Med. 1992;117:891-897.
116. Gross P. Treatment of severe hyponatremia. Kidney Int. 2001;60:2417-2427.
117. Berl T. Treating hyponatremia: damned if we do and damned if we don't. Kidney Int. 1990;37: 1006-1018.
118. Sterns RH. The treatment of hyponatremia: first, do no harm. Am J Med. 1990;88:557-560.
119. Cheung J, Zikos D, Spokicki H, et al. Long term neurologic outcome in psychogenic water drinkers with severe symptomatic hyponatremia: the effect of rapid correction. Am J Med. 1990:561.
120. Vexler ZS, Ayus JC, Roberts TP, et al. Hypoxic and ischemic hypoxia exacerbate brain injury associated with metabolic encephalopathy in laboratory animals. J Clin Invest. 1994;93:256-264.
121. Hew-Butler T, Ayus JC, Kipps C, et al. Statement of the Second International Exercise-Associated Hyponatremia Consensus Development Conference, New Zealand, 2007. Clin J Sport Med. 2008;18:111-121.
122. Mohmand HK, Issa D, Ahmad Z, et al. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clin J Am Soc Nephrol. 2007;2:1110-1117.
123. Perianayagam A, Sterns RH, Silver SM, et al. DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia. Clin J Am Soc Nephrol. 2008;3:331-336.
124. Berl T. The Adrogue-Madias formula revisited. Clin J Am Soc Nephrol. 2007;2:1098-1099.
125. Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006;119:71 e1-e8.
126. Gankam Kengne F, Andres C, Sattar L, et al. Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM. 2008;101:583-588.
127. Furst H, Hallows KR, Post J, et al. The urine/plasma electrolyte ratio: a predictive guide to water restriction. Am J Med Sci. 2000;319:240-244.
128. Berl T. Impact of solute intake on urine flow and water excretion. J Am Soc Nephrol. 2008;19: 1076-1078.
129. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int. 2006;69:2124-2130.
130. Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med. 2001;110: 582-584.
131. Saito T, Ishikawa S, Abe K, et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab. 1997;82:1054-1057.
132. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099-2112.
133. Soupart A, Gross P, Legros JJ, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol. 2006;1:1154-1160.
134. Gerbes AL, Gulberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology. 2003;124: 933-939.
135. Wong F, Blei AT, Blendis LM, et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology. 2003;37:182-191.
136. Gines P, Wong F, Watson H, et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology. 2008;48:204-213.
137. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107:2690-2696.
138. Zeltser D, Rosansky S, van Rensburg H, et al. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27:447-457.